BACKGROUND: HIV-1 drug resistance in treatment-naive patients has a significant impact on the individual patient as well as implications for the wider population. These effects are amplified in the context of resource-limited settings, which are rapidly expanding access to antiretroviral therapy. METHODS: This cross-sectional survey at a single treatment site in Kingston, Jamaica was designed to identify the prevalence of HIV-1 drug-resistant mutations in chronically infected, treatment-naive patients. Mutations were identified using the Stanford HIV database algorithm and the World Health Organization (WHO) HIV Drug Resistance (HIVDR) surveillance mutations. RESULTS: The inclusion of 103 cases in the study resulted in 79 (76.6%) amplifiable samples. Genotype analysis revealed that 12.6% (95% CI 5.3, 19.9) were identified as having clinically significant mutations, while 10.1% (95% CI 3.5, 16.7) had WHO HIVDR surveillance mutations. CONCLUSIONS: According to the WHO standard, this study population has a moderate level of HIVDR in treatment-naive patients and strongly implies the need to introduce HIVDR surveillance in Jamaica.
BACKGROUND:HIV-1 drug resistance in treatment-naive patients has a significant impact on the individual patient as well as implications for the wider population. These effects are amplified in the context of resource-limited settings, which are rapidly expanding access to antiretroviral therapy. METHODS: This cross-sectional survey at a single treatment site in Kingston, Jamaica was designed to identify the prevalence of HIV-1 drug-resistant mutations in chronically infected, treatment-naive patients. Mutations were identified using the Stanford HIV database algorithm and the World Health Organization (WHO) HIV Drug Resistance (HIVDR) surveillance mutations. RESULTS: The inclusion of 103 cases in the study resulted in 79 (76.6%) amplifiable samples. Genotype analysis revealed that 12.6% (95% CI 5.3, 19.9) were identified as having clinically significant mutations, while 10.1% (95% CI 3.5, 16.7) had WHO HIVDR surveillance mutations. CONCLUSIONS: According to the WHO standard, this study population has a moderate level of HIVDR in treatment-naive patients and strongly implies the need to introduce HIVDR surveillance in Jamaica.
Authors: Robert W Shafer; Soo-Yon Rhee; Deenan Pillay; Veronica Miller; Paul Sandstrom; Jonathan M Schapiro; Daniel R Kuritzkes; Diane Bennett Journal: AIDS Date: 2007-01-11 Impact factor: 4.177
Authors: S A Allen; R Musonda; S Trask; B H Hahn; H Weiss; J Mulenga; F Kasolo; S H Vermund; G M Aldrovandi Journal: AIDS Res Hum Retroviruses Date: 2001-07-01 Impact factor: 2.205
Authors: Cindy-Leigh C Hamilton; Lindsay M Eyzaguirre; Icolyn I Amarakoon; Peter Figueroa; Jacqueline Duncan; Jean K Carr; Marcia E Roye Journal: AIDS Res Hum Retroviruses Date: 2012-02-17 Impact factor: 2.205
Authors: V DeGruttola; L Dix; R D'Aquila; D Holder; A Phillips; M Ait-Khaled; J Baxter; P Clevenbergh; S Hammer; R Harrigan; D Katzenstein; R Lanier; M Miller; M Para; S Yerly; A Zolopa; J Murray; A Patick; V Miller; S Castillo; L Pedneault; J Mellors Journal: Antivir Ther Date: 2000-03
Authors: Patricia Cane; Ian Chrystie; David Dunn; Barry Evans; Anna Maria Geretti; Hannah Green; Andrew Phillips; Deenan Pillay; Kholoud Porter; Anton Pozniak; Caroline Sabin; Erasmus Smit; Jonathan Weber; Mark Zuckerman Journal: BMJ Date: 2005-11-18
Authors: Ravindra K Gupta; Michael R Jordan; Binta J Sultan; Andrew Hill; Daniel H J Davis; John Gregson; Anthony W Sawyer; Raph L Hamers; Nicaise Ndembi; Deenan Pillay; Silvia Bertagnolio Journal: Lancet Date: 2012-07-23 Impact factor: 79.321
Authors: Aneisha M Collins-Fairclough; Ann M Dennis; Julie A E Nelson; Sharon S Weir; J Peter Figueroa Journal: AIDS Res Hum Retroviruses Date: 2015-07-02 Impact factor: 2.205
Authors: Santiago Avila-Rios; Omar Sued; Soo-Yon Rhee; Robert W Shafer; Gustavo Reyes-Teran; Giovanni Ravasi Journal: PLoS One Date: 2016-06-29 Impact factor: 3.240
Authors: L Marije Hofstra; Elena Sánchez Rivas; Monique Nijhuis; Leonie E A Bank; Eduan Wilkinson; Karina Kelly; Tania Mudrikova; Rob Schuurman; Tulio de Oliveira; Jaclyn de Kort; Annemarie M J Wensing Journal: Clin Infect Dis Date: 2017-04-15 Impact factor: 9.079